EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†J. Alfred Witjes, Donna E. Hansel, Neeraj Agarwal et al.|European Urology|2019Cited by 191
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines CommitteesAlan Horwich, Donna E. Hansel, Marek Babjuk et al.|Annals of Oncology|2019Cited by 182
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022Silke Gillessen, Ken Herrmann, Alberto Bossi et al.|European Journal of Cancer|2023Cited by 156
Patient-derived Xenografts Reveal that Intraductal Carcinoma of the Prostate Is a Prominent Pathology in BRCA2 Mutation Carriers with Prostate Cancer and Correlates with Poor PrognosisGail P. Risbridger, Damien Bolton, Renea A. Taylor et al.|European Urology|2014Cited by 137
Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 ConsortiumMieke Van Hemelrijck, Michael Fahey, Ji Xi et al.|European Urology|2018Cited by 93